Paul G. Polakis
#123,766
Most Influential Person Now
Paul G. Polakis's AcademicInfluence.com Rankings
Paul G. Polakisphilosophy Degrees
Philosophy
#5700
World Rank
#8581
Historical Rank
Logic
#2933
World Rank
#4011
Historical Rank
Download Badge
Philosophy
Why Is Paul G. Polakis Influential?
(Suggest an Edit or Addition)Paul G. Polakis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Wnt signaling and cancer. (2000) (3361)
- Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly (1996) (1384)
- Wnt signaling in cancer. (2012) (1353)
- Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. (2000) (1341)
- Association of the APC gene product with beta-catenin. (1993) (1307)
- Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines (1997) (1207)
- Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. (1995) (1060)
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (2008) (1034)
- The many ways of Wnt in cancer. (2007) (913)
- Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3β (1998) (799)
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (2012) (789)
- The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors (1999) (751)
- Antibody Drug Conjugates for Cancer Therapy (2016) (664)
- The oncogenic activation of β-catenin (1999) (631)
- The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell (1999) (602)
- Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. (1996) (553)
- Site-specific antibody drug conjugates for cancer therapy (2013) (529)
- The adenomatous polyposis coli tumor suppressor protein localizes to plasma membrane sites involved in active cell migration (1996) (528)
- The adenomatous polyposis coli (APC) tumor suppressor. (1997) (488)
- The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. (1994) (455)
- Stabilization of beta-catenin by genetic defects in melanoma cell lines. (1997) (420)
- IQGAP1, a calmodulin‐binding protein with a rasGAP‐related domain, is a potential effector for cdc42Hs. (1996) (384)
- Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes (1996) (361)
- Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. (1998) (358)
- The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. (1999) (339)
- The oncogenic activation of beta-catenin. (1999) (313)
- The APC Protein and E-cadherin Form Similar but Independent Complexes with α-Catenin, β-Catenin, and Plakoglobin (*) (1995) (310)
- Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. (1997) (267)
- A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. (2013) (264)
- Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein (1991) (262)
- A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐catenin (1999) (256)
- Molecular cloning of a GTPase activating protein specific for the Krev-1 protein p21 rap1 (1991) (241)
- Molecular cloning and nucleic acid binding properties of the GAP-associated tyrosine phosphoprotein p62 (1992) (241)
- ras p21 and GAP inhibit coupling of muscarinic receptors to atrial K+ channels (1990) (222)
- Drugging Wnt signalling in cancer (2012) (214)
- Mutations in the APC gene and their implications for protein structure and function. (1995) (201)
- Structural basis of the Axin–adenomatous polyposis coli interaction (2000) (201)
- Deletion of an amino-terminal sequence beta-catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor suppressor protein (1996) (200)
- Wnt Isoform-Specific Interactions with Coreceptor Specify Inhibition or Potentiation of Signaling by LRP6 Antibodies (2010) (196)
- Ubiquitin Ligase RNF146 Regulates Tankyrase and Axin to Promote Wnt Signaling (2011) (185)
- Structural requirements for the interaction of p21ras with GAP, exchange factors, and its biological effector target. (1993) (183)
- Identification of a Novel Guanine Nucleotide Exchange Factor for the Rho GTPase* (1996) (175)
- Casein Kinase 1: A Wnt'er of Disconnect (2002) (163)
- Molecular cloning and expression of a G25K cDNA, the human homolog of the yeast cell cycle gene CDC42 (1990) (154)
- The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. (2007) (144)
- GAP domains responsible for ras p21-dependent inhibition of muscarinic atrial K+ channel currents. (1992) (143)
- Induction of a β-catenin-LEF-1 complex by wnt-1 and transforming mutants of β-catenin (1997) (143)
- Axin-dependent Phosphorylation of the Adenomatous Polyposis Coli Protein Mediated by Casein Kinase 1ε* (2001) (133)
- A Drosophila homolog of the tumor suppressor gene adenomatous polyposis coli down-regulates beta-catenin but its zygotic expression is not essential for the regulation of Armadillo. (1997) (126)
- Hath1, Down-Regulated in Colon Adenocarcinomas, Inhibits Proliferation and Tumorigenesis of Colon Cancer Cells (2004) (119)
- An intact hydrophobic N-terminal sequence is critical for binding of rat brain hexokinase to mitochondria. (1985) (117)
- Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer (2015) (117)
- Adenomatous Polyposis Coli Tumor Suppressor Protein Has Signaling Activity in Xenopus laevis Embryos Resulting in the Induction of an Ectopic Dorsoanterior Axis (1997) (117)
- EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer (2004) (114)
- Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer (2006) (113)
- EphB2 is a Prognostic Factor in Colorectal Cancer (2005) (111)
- Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. (1997) (109)
- Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid. (2001) (108)
- More Than One Way to Skin a Catenin (2001) (103)
- Phosphorylation of Dishevelled by Protein Kinase RIPK4 Regulates Wnt Signaling (2013) (101)
- The APC protein and E-cadherin form similar but independent complexes with alpha-catenin, beta-catenin, and plakoglobin. (1995) (92)
- A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs (2015) (92)
- Purification of a plasma membrane-associated GTPase-activating protein specific for rap1/Krev-1 from HL60 cells. (1991) (90)
- Liposomal Packaging Generates Wnt Protein with In Vivo Biological Activity (2008) (90)
- Synergistic Induction of Tumor Antigens by Wnt-1 Signaling and Retinoic Acid Revealed by Gene Expression Profiling* (2002) (84)
- Arming antibodies for cancer therapy. (2005) (82)
- Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. (2014) (80)
- Identification of the ral and rac1 gene products, low molecular mass GTP-binding proteins from human platelets. (1989) (79)
- The Human p62 cDNA Encodes Sam68 and Not the RasGAP-Associated p62 Protein (1996) (75)
- The Ubiquitin-Proteasome Pathway and Serine Kinase Activity Modulate Adenomatous Polyposis Coli Protein-mediated Regulation of β-Catenin-Lymphocyte Enhancer-binding Factor Signaling* (1999) (74)
- Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. (2007) (73)
- Defects in the regulation of β-catenin in colorectal cancer (1999) (73)
- High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers. (2018) (72)
- Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin. (1997) (67)
- Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma (2009) (64)
- 腺腫性結腸ポリープ癌抑制遺伝子のショウジョウバエ相同体はβ‐カテニンをダウンレギュレートするが,その接合体発現はアルマジロ蛋白質の調節に必須ではない (1997) (61)
- Localization of the rap1GAP catalytic domain and sites of phosphorylation by mutational analysis (1992) (59)
- HectD1 E3 Ligase Modifies Adenomatous Polyposis Coli (APC) with Polyubiquitin to Promote the APC-Axin Interaction (2012) (58)
- Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers (2015) (57)
- Regulation of Epithelial Branching Morphogenesis and Cancer Cell Growth of the Prostate by Wnt Signaling (2008) (57)
- Hath 1 , Down-Regulated in Colon Adenocarcinomas , Inhibits Proliferation and Tumorigenesis of Colon Cancer Cells (2004) (54)
- Identification and immunotherapeutic targeting of antigens induced by chemotherapy (2006) (54)
- Activation of the Wnt Pathway Interferes with Serum Response Element-driven Transcription of Immediate Early Genes* (2002) (54)
- The formylpeptide chemoattractant receptor copurifies with a GTP-binding protein containing a distinct 40-kDa pertussis toxin substrate. (1988) (52)
- An Antibody–Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of Melanoma (2011) (51)
- Isolation of GTP-binding proteins from myeloid HL-60 cells. Identification of two pertussis toxin substrates. (1987) (50)
- Differential Effects of Predosing on Tumor and Tissue Uptake of an 111In-Labeled Anti-TENB2 Antibody–Drug Conjugate (2012) (50)
- Defects in the regulation of beta-catenin in colorectal cancer. (1999) (49)
- The identification and characterization of an epidermal growth factor-stimulated phosphorylation of a specific low molecular weight GTP-binding protein in a reconstituted phospholipid vesicle system. (1990) (44)
- An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. (2015) (42)
- Characterization of G25K, a GTP-binding protein containing a novel putative nucleotide binding domain. (1989) (42)
- Formation of the blood–brain barrier: Wnt signaling seals the deal (2008) (42)
- An integrated approach to identify normal tissue expression of targets for antibody‐drug conjugates: case study of TENB2 (2013) (37)
- A blockade in Wnt signaling is activated following the differentiation of F9 teratocarcinoma cells. (2004) (36)
- Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers (2017) (34)
- Evolutionary Divergence in the Catalytic Activity of the CAM-1, ROR1 and ROR2 Kinase Domains (2014) (33)
- Phosphorylation of rap1GAP in vivo and by cAMP-dependent kinase and the cell cycle p34cdc2 kinase in vitro. (1992) (32)
- Interactions between p21ras proteins and their GTPase activating proteins. (1992) (31)
- Heterogeneous amino acids in Ras and Rap1A specifying sensitivity to GAP proteins. (1991) (30)
- Stromal Cell-Derived Factor-1/CXCL12 Contributes to MMTV-Wnt1 Tumor Growth Involving Gr1+CD11b+ Cells (2010) (29)
- A Role for Hath1, a bHLH Transcription Factor, in Colon Adenocarcinoma (2005) (28)
- Proteolytic dissection of rat brain hexokinase: determination of the cleavage pattern during limited digestion with trypsin. (1984) (27)
- GEPIS - quantitative gene expression profiling in normal and cancer tissues (2004) (26)
- Reversible Modification of Adenomatous Polyposis Coli (APC) with K63-linked Polyubiquitin Regulates the Assembly and Activity of the β-Catenin Destruction Complex (2012) (26)
- An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies (2015) (25)
- Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src (1999) (24)
- An improved and robust DNA immunization method to develop antibodies against extra-cellular loops of multi-transmembrane proteins (2014) (24)
- Functional interaction between p21rap1A and components of the budding pathway in Saccharomyces cerevisiae (1992) (23)
- Regulation of ras p21 by GTPase activating proteins. (1991) (23)
- MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma (2014) (22)
- Purification of highly bindable rat brain hexokinase by high performance liquid chromatography (HPLC). (1982) (22)
- The Melanosomal Protein PMEL17 as a Target for Antibody Drug Conjugate Therapy in Melanoma (2012) (21)
- Multiple chromatographic forms of the formylpeptide chemoattractant receptor and their relationship to GTP-binding proteins. (1989) (20)
- Mammary tumor regression elicited by Wnt signaling inhibitor requires IGFBP5. (2012) (20)
- An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer (2017) (19)
- Regulation of the GTPase activity of the ras-related rap2 protein. (1992) (17)
- Analysis of the tumor suppressor activity of the K-rev-1 gene in human tumor cell lines. (1994) (14)
- Association of a tyrosine kinase activity with GAP complexes in v-src transformed fibroblasts. (1992) (13)
- Phosphorylation of Rap1GAP during the cell cycle. (1994) (13)
- Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. (2019) (13)
- EphB 2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer (2004) (12)
- A synthetic peptide corresponding to a sequence in the GTPase activating protein inhibits p21ras stimulation and promotes guanine nucleotide exchange. (2009) (8)
- The RAP1GA1 locus for human Rap1-GTPase activating protein 1 maps to chromosome 1p36.1-->p35. (1994) (7)
- GTPase-Activating Protein (2020) (6)
- Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response (2020) (6)
- Focus Review Drugging Wnt signalling in cancer (2012) (5)
- 1598PTRANSLATIONAL PKPD OF DNIB0600A, AN ANTI-NAPI2B-VC-MMAE ADC IN OVARIAN AND NSCLC CANCERS. (2014) (4)
- Purification of baculovirus-produced Rap1 GTPase-activating protein. (1995) (4)
- Chemoattractant Receptors and Signal Transduction Processes (1988) (3)
- Compositions and methods for the diagnosis and treatment of a tumor (2000) (3)
- An Introduction to Wnt Signaling (2011) (2)
- Retinoic Acid Human Cancers and Its Synergistic Induction by Wnt-1 and in Stra 6 Overexpression of the Retinoic Acid-responsive Gene (2001) (2)
- Abstract POSTER-THER-1441: Biomarker evaluation of phase 1 clinical trials of antibody-drug conjugates (ADCs) in platinum resistant ovarian cancer (2015) (1)
- ThioMabs: improving safety abd retaining efficacy of antibody drug conjugates (2007) (1)
- Pyrrolo benzodiazepines and conjugates thereof (2011) (1)
- Evaluation of efficacy and toxicity of carcinoembryonic antigen related cell adhesion molecule (CEACAM)6 targeted immunotherapy in pancreatic adenocarcinoma (2005) (1)
- Abstract 4634: Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin's lymphoma are effective in cell lines resistant to auristatin based ADCs. (2013) (1)
- Abstract 4289: Early study on LGR5/GPR49 molecule as a potential colon cancer stem cell target for the antibody conjugated drug treatment (2010) (1)
- TenB2 as a therapeutic antibody drug target for the treatment of prostate cancer. (2007) (1)
- STRUCTURE OF THE AXIN RGS-HOMOLOGOUS DOMAIN IN COMPLEX WITH A SAMP REPEAT FROM APC (2000) (0)
- Loss of /3-Catenin Regulation by the APC Tumor Suppressor Protein Correlates with Loss of Structure Due to Common Somatic Mutations of the Gene1 (2006) (0)
- Drosophila Wnt/Wingless Signaling in (2012) (0)
- Abstract 947: An antibody drug conjugate (ADC) directed to lymphocyte antigen 6 complex, locus E (LY6E) delivers targeted chemotherapy to a wide range of solid tumor malignancies (2015) (0)
- Proliferation and Tumorigenesis of Colon Cancer Cells Hath 1 , Down-Regulated in Colon Adenocarcinomas , Inhibits (2004) (0)
- An antibody drug conjugate (ADC) directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) provides robust tumor killing in a wide range of solid tumor malignancies Running Title: Preclinical development of a LY6E antibody drug conjugate (2015) (0)
- Compositions and methods for tumor diagnosis and treatment (2005) (0)
- Molecular Cloning andExpression ofa G25KcDNA,theHuman HomologoftheYeastCellCycleGeneCDC42 (1990) (0)
- Regulation of intracellular (8-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein (2005) (0)
- Compositions and methods for diagnosis and treatment of tumors (2002) (0)
- Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer (2010) (0)
- Functional Interaction between p 2 raPlPA and Components of the Budding Pathway in Saccharomyces cerevisiae (2003) (0)
- Drugging Wnt signalling in cancer (2013) (0)
- Cancer Biology and Signal Transduction MAPK Pathway Inhibition Enhances the Ef fi cacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma (2014) (0)
- 210 POSTER Development of drug-conjugated monoclonal antibodies against MUC16 for the treatment of epithelial ovarian cancers (2006) (0)
- Armed antibodies targeted to STEAP1 inhibit growth of human prostate xenografts in vivo (2007) (0)
- Immunoconjugates comprising anti-CD79b (2013) (0)
- Abstract 5619: Preclinical development of anti-SLC34A2 antibody drug conjugate as a therapeutic for non-small cell lung and ovarian cancers. (2013) (0)
- Of Mice and Men: Therapeutic mTOR Inhibition in Polycystic Kidney Disease (2010) (0)
- CRYSTAL STRUCTURE OF THE RGS-HOMOLOGOUS DOMAIN OF AXIN (2000) (0)
- Abstract 4396: Conjugation site modulates the stability and biological activity of antibody drug conjugates (2010) (0)
- Compositions and methods for the diagnosis and treatment of a lung tumor. (2002) (0)
- A method for enhancing cancer therapy (2001) (0)
- Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer (2019) (0)
- Anticorps anti-tenb2 modifiés par des cystéines et conjugués anticorps-médicament (2008) (0)
- Anti-TENB2 antibodies engineered with cysteine, and antibody and drug conjugates (2008) (0)
- Antibodies and immunoconjugates and their use. (2007) (0)
- Immunoconjugates comprising an anti-CD22 antibody linked to a pirrolobenzodiazepina (2013) (0)
- The candidate guidance molecule, Semaphorin 5B, is over-expressed in kidney cancers (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Paul G. Polakis?
Paul G. Polakis is affiliated with the following schools:
